SK Bioscience secures 23.9B KRW vaccine contract
SK바이오사이언스
302440
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=847
Risk-adjusted indicator based on 847 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 23,897,700,000 KRW
- • Percentage of Recent Revenue: 3.67%
- • Recent Annual Revenue (2025): 651,368,342,533 KRW
- • Contract Start Date: 2026-06-23
- • Contract End Date: 2027-06-30
AI Analysis Summary
SK Bioscience Co.,Ltd. has secured a supply contract with the Public Procurement Service of Korea for influenza vaccines for the 2026-2027 season, valued at 23.9 billion KRW. This contract represents 3.67% of the company's recent annual revenue (2025). The contract period is from June 23, 2026, to June 30, 2027. While a positive development, the contract's impact is moderate given its size relative to total revenue and future delivery schedule.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.